Ruhlmann, Christina H. http://orcid.org/0000-0002-3728-273X
Jordan, Karin http://orcid.org/0000-0001-9379-5938
Jahn, Franziska http://orcid.org/0000-0002-7687-8544
Maranzano, Ernesto http://orcid.org/0000-0003-4249-4064
Molassiotis, Alex http://orcid.org/0000-0001-6351-9991
Dennis, Kristopher http://orcid.org/0000-0002-5588-1007
Funding for this research was provided by:
University Library of Southern Denmark
Article History
First Online: 15 December 2023
Declarations
:
: Christina Ruhlmann reports personal fees (speaker) from Bristol Myers Squibb (BMS), Helsinn Healthcare SA, and Pharmanovia, and funding for a clinical trial from Helsinn Healthcare SA and the Novo Nordic Foundation. Karin Jordan reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, med update GmbH, MSD, Mundipharma, onkowissen, Riemser, Roche, Shire (Takeda), and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm and Voluntis; and personal fees as author for UpToDate. Franziska Jahn reports honorarium (speaker) from Amgen. Ernesto Maranzano has none to declare. Alex Molasiotis reports honoraria and research grant from Helsinn. Kristopher Dennis has none to declare.